Cancer Policy FDA debuts precheck manufacturing program to boost domestic drug development February 06, 2026Vol.52 No.05By Claire Marie Porter
Cancer Policy NIH suspends new embryonic stem cell line submissions January 30, 2026Vol.52 No.04By Sara Willa Ernst
Cancer Policy CMS to enter negotiations with drugmakers over the price of four cancer medications January 30, 2026Vol.52 No.04By Sara Willa Ernst
Cancer Policy Tens of thousands of healthcare workers strike across the country January 30, 2026Vol.52 No.04By Sara Willa Ernst
Cancer Policy FDA delays drug reviews in new voucher program amid safety, efficacy concerns January 30, 2026Vol.52 No.04By Claire Marie Porter
Cancer Policy ACA Marketplace enrollments down by 1.4 million, early data shows January 23, 2026Vol.52 No.03By Sara Willa Ernst
Cancer Policy Workforce shortages will threaten access to cancer care, President’s Cancer Panel says in a report January 23, 2026Vol.52 No.03
Cancer Policy FDA releases 10 guiding principles for AI use in drug development January 16, 2026Vol.52 No.02By Sara Willa Ernst
Cancer Policy FDA to increase regulatory flexibility for development of cell and gene therapies January 16, 2026Vol.52 No.02By Jacquelyn Cobb
